Dr. Barry A. Ginsberg is an accomplished professional who advises executives across industries, bringing particular expertise in strategy and performance in the pharmaceuticals and medical-products sector. He also consults with healthcare companies to develop global strategies and operating models and is an experienced leader with a demonstrated history of success working as an entrepreneur in the health and wellness industry. He is skilled in comprehensive eye care, and patient education. Combined with an expansive network of contacts and an exclusive key opinion leader database throughout North America, Europe, Middle East, Asia, and South America, he brings consummate value to the SunMed team.
Dr. Ginsberg earned his Bachelor of Arts degree in Chemistry with a minor in Economics from Yeshiva University, and his Bachelor of Science and Doctorate degrees from the Pennsylvania College of Optometry. He participated in four Externships including the Feinbloom Low Vision Center in Philadelphia, focusing on Age Related Macular Degeneration (AMD) and the Goldschleger Eye Institute in Tel Hashomer Hospital in Israel, focusing on diseases of the eye including Glaucoma. Concurrently, he attended the LaSalle College MBA Program in Philadelphia.
Dr. Ginsberg’s community service participation included the Flying Samaritans and One Sight. He recently retired after practicing over 35 years in the medical field.
For the past two decades, Mr. Michaels has established lasting relationships with key business leaders and stakeholders in Japan and the U.S., particularly in the Life Sciences field. He has completed transactions that influenced companies such as Celgene Corporation, Sumitomo Pharmaceuticals, Nobelpharma Co., Ltd, Teva Pharmaceuticals, ICOS, Neurocrine, Cell Therapeutics and Gilead, to name just a few.
Paul has also provided financial leadership for almost 18 years to Inabata & Co. Ltd., one of Japan’s largest trading companies with $4.5 billion in annual sales and successfully licensed multiple drugs from Gilead (formerly Nexstar Pharmaceuticals). Throughout his tenure, he structured and closed major transactions that brought high-value products to the Japanese pharmaceutical market in addition to other corporate responsibilities that included overall evaluation of corporate asset values. Paul subsequently founded Nobelpharma, Ltd. Japan, an affiliate of Inabata & Co. Ltd., which is now one of Japan’s most profitable orphan drug companies. As President of the U.S. division and a co-Founder,he secured $35 million in initial capital and negotiated the license for the first designated orphan drug product in the company’s pipeline from Teva Pharmaceuticals.
Paul began his career as Co-Founder, Executive Vice President and Board Member of Global Capital Group, a publicly traded corporate finance firm on Wall Street where he structured, financed and advised transactions in multiple spaces utilizing a variety of financial vehicles including private placements and Initial Public Offerings.
He attended Tulane University and completed an HBX program from Harvard.
Alexander Michaels is an Analyst at SunMed Advisors and specializes in Capital Markets.
He joined SunMed Advisors at the firm’s inception and works across all sectors, particularly on issues of corporate growth, strategy and execution for both the buy and sell side transactions. In this role he uses real world uncertainty and incorporates it into NPV valuation models and Monte Carlo simulations to achieve the best end result for the client
Alexander is a graduate of Florida Gulf Coast University with a Bachelor’s degree in Finance.